Filtered By:
Source: Thrombosis and Haemostasis

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 528 results found since Jan 2013.

Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE E...
Source: Thrombosis and Haemostasis - March 22, 2018 Category: Hematology Authors: Gibson CM, Hankey GJ, Nafee T, Welsh RC Tags: Thromb Haemost Source Type: research

Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution.
Abstract Stroke prevention is a key clinical concern in the management of patients with atrial fibrillation. Oral anticoagulation treatment reduces the risk of disabling stroke, but the treatment increases the risk of bleeding. For decades, the decision to initiate oral anticoagulation has been guided by clinical risk scoring systems such as the CHADS2 and CHA2DS2-VASc scores. In this narrative review, we focus on the recent discussion of the "Sc" (Sex Category) criterion in the CHA2DS2-VASc score. Epidemiological considerations when assessing stroke rates in cohorts are discussed, and the implications of differen...
Source: Thrombosis and Haemostasis - April 20, 2020 Category: Hematology Authors: Nielsen PB, Overvad TF Tags: Thromb Haemost Source Type: research

Immunity in Stroke: The Next Frontier
Thromb Haemost. 2022 Jun 10. doi: 10.1055/s-0042-1748890. Online ahead of print.ABSTRACTTranslational stroke research has long been focusing on neuroprotective strategies to prevent secondary tissue injury and promote recovery after acute ischemic brain injury. The inflammatory response to stroke has more recently emerged as a key pathophysiological pathway contributing to stroke outcome. It is now accepted that the inflammatory response is functionally involved in all phases of the ischemic stroke pathophysiology. The immune response is therefore considered a breakthrough target for ischemic stroke treatment. On one side,...
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Ting Li Arthur Liesz Source Type: research

Essen Stroke Risk Score Predicts Clinical Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Evidence From the TOPCAT trial
This study sought to determine whether the Essen Stroke Risk Score (ESRS) could predict the risks of adjudicated clinical outcomes in patients with Heart failure with preserved ejection fraction (HFpEF) from the TOPCAT trial. Of 3,441 HFpEF patients with a mean follow-up of 3.3 years, the risk of stroke ranged from 0.32% per year at an ESRS of 1-2 points to 1.71% per year at a score of ≥6 points. Each point increase in ESRS was associated with increased risks of stroke (HR=1.33 [95% CI 1.16-1.53]) with a C-index of 0.68, as well as myocardial infarction (HR=1.60 [95% CI 1.40-1.83]; C-index, 0.75), HF hospitalization (HR=...
Source: Thrombosis and Haemostasis - August 29, 2022 Category: Hematology Authors: Wengen Zhu Yalin Cao Min Ye Hulin Huang Yuzhong Wu Jianyong Ma Yugang Dong Xiao Liu Chen Liu Gregory Yh Lip Source Type: research

The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its aetiology, severity and prognosis
CONCLUSIONS: The use of the SWATH-MS in thrombi from IS patients has provided new insights of pathways and players involved in its aetiology, severity and prognosis. The prominent role of the innate immune system identified might pave the way for the development of new biomarkers and therapeutic approaches in this disease.PMID:37100394 | DOI:10.1016/j.jtha.2023.04.015
Source: Thrombosis and Haemostasis - April 26, 2023 Category: Hematology Authors: Chary Lopez-Pedrera Rafael Oteros Alejandro Ib áñez-Costa Mar ía Luque-Tévar Laura Mu ñoz-Barrera Nuria Barbarroja Eduardo Chicano-G álvez Juan Marta-Enguita Josune Orbe Francisco Velasco Carlos Perez-S ánchez Source Type: research

Circulating desphospho-uncarboxylated matrix Gla protein and the risk of coronary heart disease and stroke.
CONCLUSION: The average follow-up was 11.5 years. Dp-ucMGP concentrations were not associated with CHD risk with a HR per SD of 1.00 (95% CI: 0.93-1.07) and a HR Q4 vs Q1 of 0.94 (95% CI: 0.79-1.13) after adjustment for cardiovascular risk factors. Dp-ucMGP was not associated with stroke risk (HRSD 0.98;95% CI: 0.90-1.08 and a HR Q4 vs Q1 of 1.09;95% CI: 0.78-1.51). This study could not confirm that high dp-ucMGP concentrations, reflecting a poor vitamin K status, are associated with increased CHD or stroke risk in the general population. This article is protected by copyright. All rights reserved. PMID: 24826813 [Pub...
Source: Thrombosis and Haemostasis - May 15, 2014 Category: Hematology Authors: Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, Beulens JW Tags: J Thromb Haemost Source Type: research

Differential impact of unrecognised brain infarction on stroke outcome in non-valvular atrial fibrillation.
This study enrolled 631 patients with NVAF having no clinical stroke history. UBIs were categorised into three types as territorial, lacunar, or subcortical. We collected stroke severity, functional outcome at three months, and the total volume of UBIs and acute infarction lesions. We investigated the association between clinical outcome and the type or volume of UBI, using a linear mixed model and logistic regression analysis. UBIs were detected in 285 (45.2 %) patients; territorial UBIs were observed in 24.4 % of patients (154/631), lacunar UBIs in 25 % (158/631), and subcortical UBIs in 15.7 % (99/631). Although...
Source: Thrombosis and Haemostasis - September 18, 2014 Category: Hematology Authors: Song TJ, Kim J, Lee HS, Nam CM, Nam HS, Kim EH, Lee KJ, Song D, Heo JH, Kim YD Tags: Thromb Haemost Source Type: research

Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
This study examined whether prestroke anticoagulation with rivaroxaban, a novel direct factor Xa inhibitor, influences stroke severity, thrombin-mediated intracerebral thrombus formation and pro-inflammatory processes in a rat model of brain ischaemia/reperfusion injury. Male Wistar rats were anticoagulated with rivaroxaban and subjected to 90 minutes of transient middle cerebral artery occlusion. Infarct size, functional outcome and the occurrence of intracranial haemorrhage (ICH) were assessed until day 7. Thrombin generation was determined by measuring the amount of thrombin/antithrombin complex. Intracerebral thrombus ...
Source: Thrombosis and Haemostasis - October 22, 2015 Category: Hematology Authors: Dittmeier M, Kraft P, Schuhmann MK, Fluri F, Kleinschnitz C Tags: Thromb Haemost Source Type: research

The VWF-GPIb axis in ischaemic stroke: lessons from animal models.
Abstract Stroke is a leading cause of death and long-term disability worldwide. Ischaemic stroke is caused by a blood clot that obstructs cerebral blood flow. Current treatment mainly consists of achieving fast reperfusion, either via pharmacological thrombolysis using tissue plasminogen activator or via endovascular thrombectomy. Unfortunately, reperfusion therapy is only available to a limited group of patients and reperfusion injury can further aggravate brain damage. Hence, there is an urgent need for better understanding of ischaemic stroke pathophysiology in order to develop novel therapeutic strategies. In ...
Source: Thrombosis and Haemostasis - March 30, 2016 Category: Hematology Authors: Denorme F, De Meyer SF Tags: Thromb Haemost Source Type: research

Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
This article focuses on three randomised controlled trials (RCTs) that are investigating the utility of rivaroxaban, a direct, oral, factor Xa inhibitor, in additional areas of stroke prevention where data for anticoagulants are lacking: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment (PIONEER AF-PCI); New Approach riVaroxoban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS); and Global study comparing a rivAroxaban-based antithrombo...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Hemmrich M, Peterson ED, Thomitzek K, Weitz JI Tags: Thromb Haemost Source Type: research

The C-reactive protein gene polymorphism predicts the risk of thromboembolic stroke in atrial fibrillation: a more than 10-year prospective follow-up study.
CONCLUSION: The CRP gene triallelic polymorphism and the CRP level are associated with the risk of incident thromboembolic stroke in patients with AF. This article is protected by copyright. All rights reserved. PMID: 28498565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 12, 2017 Category: Hematology Authors: Chang SN, Lai LP, Chiang FT, Lin JL, Hwang JJ, Tsai CT Tags: J Thromb Haemost Source Type: research

Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
CONCLUSION:  Use of warfarin with a therapeutic intensity or standard-dosed NOACs was associated with a relatively mild stroke in the patients with NVAF. PMID: 30453351 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Jung YH, Choi HY, Lee KY, Cheon K, Han SW, Park JH, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim YD Tags: Thromb Haemost Source Type: research